Multilayered Methylphenidate Tablet for Rebound Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Methylphenidate treatments for ADHD and ADD often result in significant variation in efficacy and rebound effects, leading to adverse symptoms such as increased aggression, mood instability, and irritability, particularly in patients with comorbid conditions like autism spectrum disorder.
Innovation Solution
A solid, oral pharmaceutical composition with a multilayered structure including a core of methylphenidate or its salt, a sustained release layer, and a delayed release layer, designed to provide a non-linear in vivo absorption model using Weibull or sigmoid functions, reducing variability in plasma concentrations and minimizing rebound effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylphenidate is administered as a conventional formulation, then the drug provides therapeutic effects for ADHD and ADD, but the drug causes rebound effects and significant variation in efficacy as it is metabolized
Solution Approach 1:
The patent divides the methylphenidate dose into multiple release phases using a multilayered tablet structure with different coating layers (enteric coating, sustained-release matrix, and immediate-release components). This segmentation allows the drug to be released in a controlled sequence, maintaining consistent plasma levels and preventing the sharp decline that causes rebound effects.
Solution Approach 2:
The patent incorporates an enteric coating layer that protects the methylphenidate from premature release in the stomach and ensures delayed release in the intestine. This preliminary protective action prevents early drug release and absorption, establishing a controlled release profile that maintains efficacy consistency and avoids rebound.
2Duration of action of moving object
If methylphenidate is administered to provide sustained therapeutic effects, then the treatment duration is extended, but the plasma concentration variation increases leading to adverse symptoms
Solution Approach 1:
The patent applies different release characteristics to different portions of the tablet through multilayered coating structures. The immediate-release portion provides initial therapeutic effect, while the sustained-release matrix maintains plasma levels over an extended period. This local differentiation of release properties allows both extended duration and stable plasma concentration.
Solution Approach 2:
The patent uses a composite tablet structure combining multiple materials with different release properties: enteric coating materials, sustained-release matrix materials, and immediate-release components. This composite structure enables the tablet to provide both extended therapeutic duration and stable plasma concentration by leveraging the complementary release characteristics of each material.
Data Source
AI summary
A solid, oral pharmaceutical composition is described. The solid, oral pharmaceutical composition includes methylphenidate or a pharmaceutical salt thereof, wherein an in vivo absorption model of the solid, oral pharmaceutical composition has a function selected from the group consisting of: a single Weibull function, a double Weibull function, and a sigmoid eMax function. A correlation of a plurality of fractions of an in vitro dissolution of the solid, oral pharmaceutical composition with a same plurality of fractions of an in vivo absorption of the solid, oral pharmaceutical composition is non-linear. A method of treating a condition in a subject having a disorder or condition responsive to the administration of methylphenidate is also described. The method includes orally administering to the subject an effective amount of the solid, oral pharmaceutical composition.